Drugmakers Lash Back at Insurers in War of Words Over Rx Prices

After enduring a rhetorical bashing over the cost of hepatitis C wonder drug Sovaldi, drug manufacturers released a study this week documenting the high cost-sharing rates charged by some insurers on health plans sold through the public exchanges.

The pharmaceutical industry is fighting back.

After enduring a rhetorical bashing over the cost of hepatitis C wonder drug Sovaldi, drug manufacturers released a study this week documenting the high cost-sharing rates charged by some insurers on health plans sold through the public exchanges.

The study was conducted by the consulting firm Avalere Health on behalf of Pharmaceutical Research and Manufacturers of America, the main industry group. It looked at drug formularies on 123 silver plans, which are designed to cover 70% of medical costs, including at least one plan sold in the largest city in every state.

Read the full story here: http://bit.ly/1qkmDOp

Source: Modern Healthcare